Posted on 05/08/2020 9:19:33 AM PDT by libh8er
New Delhi: After the United States and Japan authorised the use of experimental drug remdesivir to treat Covid-19 patients, the government of India has also begun weighing its options.
The Ministry of Health and Family Welfare held a video conference Thursday with top pharmaceutical companies to check the “status” of the drug’s development in India.
According to industry sources, major players like Cipla, Glenmark and Dr Reddy’s are working on the development of the injectable drug, which has been developed by Gilead Sciences in the US, and is under patent protection until 2035. Gilead has given the drug the brand name Veklury.
Representatives of all three aforementioned firms, along with other Indian pharma companies including Jubilant Life Sciences and Hetero Pharma, attended the meeting chaired by health ministry joint secretary Sudhanshu Pant.
“The objective of the meeting was to understand the latest status of remdesivir’s development in India,” a government source told ThePrint.
“The industry was asked if companies have reached out to Gilead Sciences, the maker of remdesivir, to initiate talks about voluntary licencing. The ministry also sought details on the process of production once Gilead gives approval, and in how much time the production can be ramped up,” the source said.
The moves come after a clinical trial showed that the use of remdesivir can reduce the time taken to recover from Covid-19 by a third.
Cipla and Jubilant Life Sciences refused to comment on the meeting or the status of remdesivir development in India, while emails sent to Glenmark, Dr Reddy’s and Hetero did not elicit a response until the publication of this report.
Steps to produce the drug in India
First, Gilead will have to give its approval for Indian companies to manufacture the drug, which will most likely be in the form of a voluntary licencing arrangement, under which it will transfer technology.
An industry insider, who was involved in the technology transfer process when Gilead allowed Indian drug makers to produce the Hepatitis C drug Sovaldi in 2014, explained: “After signing the agreement, Gilead will transfer the technology through which Indian companies will start producing the active pharmaceutical ingredients (APIs). These APIs will then be converted into injectable formulations.”
The insider added: “The first few lots will be produced at a small scale to check the production quality. After that, full scale production can be started.”
Remdesivir has ‘clear-cut’ positive effects
Last month, Dr Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said: “The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery.”
Patients who were administered the drug, Fauci said, were discharged from the hospital in 11 days, on average, as compared to 15 days for a placebo group, which took dummy or no pills.
“What it has proven is that a drug can block this virus,” Fauci said, referring to data from a study of more than 1,000 patients across the US and around the world. He said the drug would become part of standard Covid-19 care in the US.
However, Fauci’s claims came at a time when another study in medical journal The Lancet suggested the drug had not shown significant clinical benefits in critically-ill Covid-19 patients.
Well...how about NEVER!
3% less deaths and hospital stay cut by a 3rd is not a big deal.
some powers the be will have a big problem with it.
It is not a trivial thing to make it chemically. There is a number of asymmetric centers in the molecule defining it’s exact spatial structure and making chemistry and overall final purity complicated. This probably explains, in part, the high cost of remdesivir.
Where did you get the “3% less deaths” figure? I didn’t see it in the article.
Doesn’t matter to the Deep State as long as Trump’s drug (HCL) is discredited.
...Steps to produce the drug in India
First, Gilead will have to give its approval for Indian companies to manufacture the drug, which will most likely be in the form of a voluntary licencing arrangement, under which it will transfer technology.
An industry insider... explained: “After signing the agreement, Gilead will transfer the technology through which Indian companies will start producing the active pharmaceutical ingredients (APIs). These APIs will then be converted into injectable formulations.”
*************************************************************
Build up AMERICAN capabilities to produce the AMERICAN DEVELOPED drug commercially. We need robust pharmaceutical manufacturing infrastructure HERE in OUR COUNTRY. Haven’t we learned the downside of technology transfers and moving production capabilities to foreign Nations by now?
Who owns the patents?
That's exactly it. The mediatards and the Deep State have no stake in Remdesivir or HCQ. To them it's all about a drug touted by Trump as the big hope being supplanted by something else. That to them is a defeat for Trump and a victory for them.
And here we see the difference between China and honest countries. India is talking about licensing the manufacture from the company that developed it. China is trying to steal it.
I read that CCP holds the patent on Remdesivir and that Soros and gates are major contributors to Gilead development, not to mention shorty, Dr. Fauci.
I read that CCP holds the patent on Remdesivir and that Soros and gates are major contributors to Gilead development, not to mention shorty, Dr. Fauci.
Did you read the article?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.